Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

This multicenter phase 2 study of the European Myeloma Network investigated the combination of carfilzomib, thalidomide, and dexamethasone (KTd) as induction/consolidation therapy for transplant-eligible patients with previously untreated multiple myeloma (N = 91). During KTd induction therapy, pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Sonneveld, Pieter, Asselbergs, Emilie, Zweegman, Sonja, van der Holt, Bronno, Kersten, Marie Jose, Vellenga, Edo, van Marwijk-Kooy, Marinus, Broyl, Annemiek, de Weerdt, Okke, Lonergan, Sarah, Palumbo, Antonio, Lokhorst, Henk
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4300390/
https://ncbi.nlm.nih.gov/pubmed/25398935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-576256
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados